Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVERPEPCOV: Ivermectin post-exposure prophylaxis for COVID-19 in high-risk contacts in Lagos
PACTR202102848675636Phase 2Not yet recruiting
- Sponsor
- Federal Government of Nigeria
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ivermectin with Placebo (2 arms). Primary endpoints: Onset of clinical COVID-19 within 14 days confirmed by RT-PCR and Number developing COVID-19 clinical disease. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202102848675636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102848675636.